The administration of a serotonin reuptake inhibitor may lead to extra pyramidal signs, as reported in the literature. The risk seems to be increased in elderly people. We describe a case of acute dystonic reaction to paroxetine treatment in an elderly patient, who presented with a bipolar affective disorder. The underlying mechanism, possibly generated in the subcortical motor areas, is linked to changes that occur in the pharmacokinetic variables, the decreased neuroplasticity of ageing neurones and to previous exposure to neuroleptic medications.
Altshulter L L, Pierre J M, Wirshing W C, et al. (1994) Sertraline and akathisia. J Clin Psychopharmacol14: 278–279
2.
Arya D K, McKenzie J, Worrall N (1995) Exacerbation of extra pyramidal symptoms with paroxetine. Aust NZ J Psychiatry29: 51–52
3.
Azmitia E C (1978) The serotoninergic-producing neurons of the midbrain median and dorsal raphe nuclei. In Iversen L L, Iversen S D, Snyder S H (eds), Handbook of psychopharmacology, vol. 9: chemical pathways in the brain, pp. 233–314. Plenum Press, New York
4.
Baldassano C F, Truman C J, Nierenberg A, Ghaemi S N, Sachs G S (1996) Akathisia: a review and case report following paroxetine treatment. Compr Psychiatry37: 122–124
5.
Baldessarini R J, Marsch E (1990) Fluoxetine and side effects. Archs Gen Psychiatry47: 191–192
6.
Baldwin D, Fineberg N, Montgomery S (1991) Fluoxetine, fluvoxamine and extrapyramidal tract disorders. Int Clin Psychopharmacol6: 51–58
7.
Blier P, Montigny C, Chaput Y (1990) A role for the serotonin system in the mechanism of action of antidepressants. J Clin Psychiatry51: 14–20
8.
Bouchard R H, Poucher E, Vincent P (1989) Fluoxetine and extra pyramidal side effects. Am J Psychiatry146: 1352–1353
9.
Byerley W F, McConnell E J, McCabe R T, Dawson T M, Grosser B I (1988) Decreased beta-adrenergic receptors in rat brain after chronic administration of the selective rerotonin reuptake inhibitor fluoxetine. Psychopharmacology94: 141–143
10.
Caley C F (1998) Extra pyramidal reactions from concurrent SSRI and atypical antipsychotic use. Int J Psychiatr Med15: 76–79
11.
Caley C F, Friedman J H (1992) Does fluoxetine exacerbate Parkinson's disease?J Clin Psychiatry53: 278–282
12.
Davies J, Tonogroach P (1978) Neuropharmacologic studies on the nigro striatal and raphe striatal system in the rat. Eur J Pharmacol51: 91–100
13.
Dray A (1981) Serotonin in the basal ganglia: functions and interactions with other neuronal pathways. J Physiol (Paris)77: 393–403
14.
Edwards J G, Anderson I (1999) Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs57: 507–533
15.
Faherty C J, Harkin A J, Leonard B E (1998) The functional sensitisation of sigma receptors following chronic selective reuptake inhibitor treatment. Eur J Pharmacol346: 15–21
16.
Farragher B, Walsh N (1997) Delayed onset of extra pyramidal side effects on combining paroxetine with risperidone. Int J Psychiatr Med14: 117–118
17.
Fibiger H C, Lloyd K G (1984) Neurobiological substrates of tardive dyschinesia: the GABA hypothesis. Trends Neurosci7: 462–464
18.
Hansen L (2002) A critical review of akathisia and in possible association with suicide. Hum Psychopharmacol, in press
19.
Hoaken P C S (1995) An alert to extrapyramidal side effects from SSRI's. Can J Psychiatry40: 51-51
20.
Johnson A M (1991) The comparative pharmacological properties of selective serotonin reuptake inhibitors in animal. In Feighner J P, Boyer W F (eds), Selective serotonin reuptake inhibitors. Perspectives in psychiatry, vol. 1, pp. 37–70. John Wiley, Chirchester
21.
Klimek V, Nielson M (1987) Chronic treatment with anti-depressants decreases the number of (3H) SCH23390 binding sites in rat striatum and limbic system. Eur Pharmacol139: 163–169
22.
Lauterbach E C (1994) Reversible intermittent rhytmic myoclonus with fluoxetine in presumed Pick's disease. Mov Disord9: 343–346
23.
Leitner M L, Hohmann A G, Patrick S L, Walker J M (1994) Regional variation in the ratio of sigma 1 to sigma 2 binding in rat brain. Eur J Pharmacol259: 65–69
24.
Leo R J (1996) Movement disorder associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry57: 449–454
25.
Leonard B E, Faherty C J (1996) SSRIs and movement disorders: Is serotonin the culprit?Human Psychopharmacol11: S75-S82
26.
Mander A, McCausland M, Workman B, Flamer H, Christophidis N (1994) Fluoxetine induced dyskinesia. Aust NZ J Psychiatry28: 328–330
27.
Mitchell P B (1994) Selective serotonin reuptake inhibitors: adverse effects, toxicity and interactions. Adv Drug React Toxic Rev13: 121–144
28.
Nicholson S D (1992) Extra pyramidal side effects associated with paroxetine. West Eng Med J107: 90–91
29.
Prisco S, Esposito E (1995) Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Br J Pharmacol116: 1923–1931
30.
Shihabuddin L, Rapport D (1994) Sertraline and extrapyramidal side effects. Am J Psychiatry151: 288-288
31.
Sulser F, Mishra R (1982) Regulation of central noradrenergic receptor function and its relevance to therapy of depression. In Langer SZ, Takahashi R, Briley M (eds), New vistas in depression, pp. 37–47. Pergamon Press, Oxford
32.
Vetulani J, Antkiewicz-Michaluk L, Rokosz-Pelc A, Pilc A (1984) Alpha up-beta down adrenergic regulation: a possible mechanism of action of antidepressant treatments. Pol J Pharmacol Pharm36: 231–248
33.
Wils V (1992) Extra pyramidal symptoms in a patient treated with fluvoxamine. J Neurol Neurosurgery Psychiatry55: 330–331
